EID Parry Q1: Consol PAT Falls 42% YoY to ₹142 Cr, But Clears the Post-Q4-Loss Recovery Bar

E.I.D.-Parry's consolidated (primary basis) revenue rose 3.4% YoY to ₹9,017.52 Cr, but EBITDA fell to ₹781 Cr from ₹895 Cr and PAT attributable to owners dropped 42% YoY to ₹141.60 Cr (₹142 Cr per the company's press release) from ₹246 Cr; on the statement's total-PAT line (including non-controlling interest) profit was ₹311.50 Cr versus ₹464.46 Cr YoY, down 33%. Neither the current nor the year-ago quarter carried exceptional items at the consolidated level, so this YoY comparison is clean and the correct primary read: margin compression with profit declining despite revenue growth. Sequentially the swing looks dramatic — from a ₹287.17 Cr consolidated loss (₹333.30 Cr owners' loss) in Q4FY26 to this quarter's profit — but Q4 carried ₹478.38 Cr of one-off PSRIPL sugar-refinery closure charges (impairment, guarantee remeasurement, PP&E write-down), and the company itself states current and prior quarters aren't comparable due to seasonality, so that QoQ turnaround is not the headline story.

The drivers: Farm Inputs (Coromandel) remained the group's profit engine but its PBIT fell 12.4% YoY to ₹649 Cr from ₹741 Cr. Sugar & Biofuel's consolidated LBIT widened to ₹58 Cr from ₹30 Cr YoY even as the standalone Sugar segment grew revenue 18% YoY to ₹410 Cr on higher volumes — those gains were offset by higher operating costs including one-time items, leaving standalone Sugar LBIT flat at ₹49 Cr. Consumer Products (CPG) revenue nearly halved YoY to ₹94.20 Cr from ₹187.99 Cr, yet its LBIT loss narrowed to ₹11.98 Cr from ₹17.47 Cr YoY and from ₹32.65 Cr in the Q4 base — a sign of cost discipline rather than the top-line stabilization our pre-result preview flagged as a watch item. Nutraceuticals turned to near-breakeven (LBIT -₹0.11 Cr vs -₹10 Cr YoY) on a stronger US Nutraceuticals Inc. Standalone parent-level loss widened to ₹89.29 Cr (EPS -₹5.02) from ₹27.92 Cr YoY, almost entirely tied to a net ₹18.68 Cr impairment on its PSRIPL investment as that subsidiary's refinery closure winds down.

The stock went into the print at ₹772.5, down 0.8% over the past month of trading.

Our pre-result preview, published after Q4's ₹333 Cr consolidated loss, framed this print as a credibility test and set an expectation of consolidated PAT in the breakeven-to-₹15 Cr range; the actual owners' PAT of ₹141.60 Cr clears that bar by nearly 10x, resolving the watch item "Is Q1 PAT Positive & Credibly Above ₹15 Cr?" decisively in the affirmative. That said, the pre-result Street read carried a consensus SELL (67 analysts, downgraded August 4) with the 12-month target cut to ₹1,166 and FY27 EPS trimmed 26% to ₹55.80 on a 5.40% margin assumption — this quarter's YoY profit erosion and margin compression are directionally consistent with the recovery doubts embedded in that downgrade, even as the absolute number beat the acute post-crisis bar. Management's prior guidance centered on CPG reaching breakeven within 6-8 quarters and on ethanol-blending upside; this print, the first quarter of that window, shows CPG's loss narrowing but revenue nearly halving YoY, so the trajectory is only partly consistent with that guidance and no fresh management commentary in this filing extract confirms whether the timeline is on track.